Large-scale proteomic panels are actively evolving to include larger repertoires of proteins; thus, as datasets grow and validation of findings improves, ranges can be generated for various GBM clinical feature sets, and markers displayed in Figure 2B can be potentially employed to predict MGMT status. Here, MGMT is linked to glioblastoma.